AU2019346585B2 - Polymorphic compounds and uses thereof - Google Patents

Polymorphic compounds and uses thereof Download PDF

Info

Publication number
AU2019346585B2
AU2019346585B2 AU2019346585A AU2019346585A AU2019346585B2 AU 2019346585 B2 AU2019346585 B2 AU 2019346585B2 AU 2019346585 A AU2019346585 A AU 2019346585A AU 2019346585 A AU2019346585 A AU 2019346585A AU 2019346585 B2 AU2019346585 B2 AU 2019346585B2
Authority
AU
Australia
Prior art keywords
compound
solid form
disease
peaks
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019346585A
Other languages
English (en)
Other versions
AU2019346585A1 (en
Inventor
Lisa Michelle Grove
David T. Jonaitis
Russell Birch Poe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astrocyte Pharmaceuticals Inc
Original Assignee
Astrocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrocyte Pharmaceuticals Inc filed Critical Astrocyte Pharmaceuticals Inc
Publication of AU2019346585A1 publication Critical patent/AU2019346585A1/en
Application granted granted Critical
Publication of AU2019346585B2 publication Critical patent/AU2019346585B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2019346585A 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof Active AU2019346585B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736979P 2018-09-26 2018-09-26
US62/736,979 2018-09-26
PCT/US2019/053076 WO2020069068A1 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Publications (2)

Publication Number Publication Date
AU2019346585A1 AU2019346585A1 (en) 2021-04-29
AU2019346585B2 true AU2019346585B2 (en) 2025-02-27

Family

ID=69885558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019346585A Active AU2019346585B2 (en) 2018-09-26 2019-09-26 Polymorphic compounds and uses thereof

Country Status (12)

Country Link
US (2) US10765693B2 (https=)
EP (1) EP3856741A4 (https=)
JP (2) JP2022502405A (https=)
KR (1) KR20210093864A (https=)
CN (1) CN112930349A (https=)
AU (1) AU2019346585B2 (https=)
BR (1) BR112021005290A2 (https=)
CA (1) CA3113250A1 (https=)
EA (1) EA202190576A1 (https=)
IL (1) IL281718A (https=)
MX (1) MX2021003515A (https=)
WO (1) WO2020069068A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445368B1 (en) 2016-04-21 2024-07-17 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
CN112218638A (zh) 2018-02-09 2021-01-12 阿斯特罗赛特制药公司 用于治疗成瘾和相关病症的化合物和方法
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
IL310045A (en) 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
KR20240122782A (ko) * 2021-11-22 2024-08-13 아스트로사이트 파마슈티컬스, 인코포레이티드 신경학적 및 심혈관 상태를 치료하는 방법
WO2024097387A1 (en) * 2022-11-03 2024-05-10 Astrocyte Pharmaceuticals, Inc. Compositions for intravenous administration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
WO2019157317A1 (en) * 2018-02-09 2019-08-15 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995002604A1 (en) 1993-07-13 1995-01-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US6586413B2 (en) 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7087589B2 (en) * 2000-01-14 2006-08-08 The United States Of America As Represented By The Department Of Health And Human Services Methanocarba cycloakyl nucleoside analogues
US7589075B2 (en) 2001-01-16 2009-09-15 Can-Fite Biopharma Ltd. Use of an adenosine A3 receptor agonist for inhibition of viral replication
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
GB0405009D0 (en) * 2004-03-05 2004-04-07 Cambridge Biotechnology Ltd Analgesics
JP2008512457A (ja) 2004-09-09 2008-04-24 アメリカ合衆国 Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
WO2006091905A1 (en) * 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
WO2007020018A1 (en) 2005-08-12 2007-02-22 Universite Libre De Bruxelles Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies
EP2049127B1 (en) 2006-05-23 2014-11-26 University of Connecticut N-methanocarba derivatives to treat cardiac diseases
WO2008021552A2 (en) 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
US7867983B2 (en) 2007-03-29 2011-01-11 The University Of Connecticut Methods to protect skeletal muscle against injury
JP5592262B2 (ja) 2007-10-15 2014-09-17 キャン−ファイト・バイオファーマ・リミテッド 肝細胞の増殖を誘導する方法及びその使用
CN101925610A (zh) 2007-11-23 2010-12-22 巴尔-伊兰大学 不可水解的二磷酸核苷或三磷酸核苷衍生物及其用途
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
AU2009231978C1 (en) 2008-03-31 2014-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 adenosine receptor- selective agonists
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
EP2331542B1 (en) 2008-08-01 2016-07-27 The United States of America, as Represented by The Secretary, Department of Health and Human Services A3 adenosine receptor antagonists and partial agonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
US8685372B2 (en) 2009-04-15 2014-04-01 The Regents Of The University Of California Peptides and aptamers for targeting of neuron or nerves
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
US8822434B2 (en) 2010-02-22 2014-09-02 The University Of Connecticut Compositions and methods to treat cardiac diseases
US8691775B2 (en) 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
US9132131B2 (en) 2011-04-21 2015-09-15 Saint Louis University Use of adenosine A3 receptor agonists for treatment of neuropathic pain
US20140241990A1 (en) 2011-09-30 2014-08-28 Tufts University Methods of using adenosine a1 receptor activation for treating depression
SI2968385T1 (sl) 2013-03-13 2018-10-30 Tufts University Uridin nukleozid derivati, sestavki in metode uporabe
US9963450B2 (en) 2013-11-27 2018-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists
HK1247119A1 (zh) 2015-02-04 2018-09-21 贝克心脏与糖尿病研究所 一种治疗方法和用於所述治疗方法中的化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017185061A1 (en) * 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
US20180021363A1 (en) * 2016-04-21 2018-01-25 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating neurological and cardiovascular conditions
WO2019157317A1 (en) * 2018-02-09 2019-08-15 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Balbach, S. et al., "Pharmaceutical evaluation of early development candidates "the 100 mg-approach", International Journal of Pharmaceutics. 2004, vol. 275, pages 1-12 *
Bastin, R. J. et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities", Organic Process Research & Development. 2000, vol 4, 427-435 *
Caira, M. R., "Crystalline Polymorphism of Organic Compounds", Design of organic solids, Weber, E. et al "ED", Springer, 1998, pages 164-208 *
Singhal, D. et al., "Drug polymorphism and dosage form design: a practical perspective", Advanced Drug Delivery Reviews. 2004, vol. 56, pages 335-347 *

Also Published As

Publication number Publication date
NZ774215A (en) 2025-03-28
CA3113250A1 (en) 2020-04-02
JP2022502405A (ja) 2022-01-11
WO2020069068A9 (en) 2020-05-14
KR20210093864A (ko) 2021-07-28
MX2021003515A (es) 2021-05-27
US11324769B2 (en) 2022-05-10
WO2020069068A1 (en) 2020-04-02
US20200093848A1 (en) 2020-03-26
JP2024114885A (ja) 2024-08-23
US10765693B2 (en) 2020-09-08
CN112930349A (zh) 2021-06-08
EP3856741A1 (en) 2021-08-04
EP3856741A4 (en) 2022-06-22
AU2019346585A1 (en) 2021-04-29
EA202190576A1 (ru) 2021-09-03
US20210077518A1 (en) 2021-03-18
IL281718A (en) 2021-05-31
BR112021005290A2 (pt) 2021-06-22

Similar Documents

Publication Publication Date Title
AU2019346585B2 (en) Polymorphic compounds and uses thereof
CN107501177B (zh) 脯氨酰羟化酶抑制剂的晶体形态
CA3000483C (en) Compounds, compositions, and methods for modulating cftr
TWI516488B (zh) 嘧啶并［６，１－ａ］異喹啉－４－酮化合物之結晶型
CA3056426A1 (en) Quinolinyl compounds and their use as a kappa opioid receptor (kor) antagonists and products and methods related thereto
MX2015000783A (es) Antagonistas del receptor de 5-hidroxitriptamina 3 (5-ht3).
CN109071524A (zh) 作为eaat2活化剂的哒嗪衍生物
US20240368164A1 (en) Purine nucleosides, their intermediates, and methods of preparation thereof
EP3978478B1 (en) Tetrahydro-1h-benzazepine compound as potassium channel modulator, preparation method and use thereof
WO2025006827A1 (en) Substituted cyclic compounds and methods of treating phenylketonuria and other amino acidurias
EA046380B1 (ru) Полиморфные формы соединения a и их фармацевтические композиции
EP4178961A1 (en) Polymorphs of a gabaa alpha5 agonist and methods of using in the treatment of cognitive impairment
TW200526642A (en) Heterocyclic derivatives
EP4573081A1 (en) Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
WO2024144874A2 (en) Fast-dissolving dosage forms and uses thereof
HK40093043A (zh) GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
JP2021509398A (ja) 二重作用ｆｋｂｐ１２およびｆｋｂｐ５２阻害剤
HK40003887A (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241367A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365A1 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365B (en) Crystalline forms of a prolyl hydroxylase inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)